Alexion Eyes Soliris' Japan Launch, Analysts Upbeat About Pricing And Market Size
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare recently approved Alexion Pharmaceutical's Soliris (eculizumab) for the rare blood disorder paroxysmal nocturnal hemoglobinuria, and analysts believe it may beat initial expectations once it hits the market